<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TENORETIC- atenolol and chlorthalidone tablet </strong><br>AstraZeneca Pharmaceuticals LP<br></p></div>
<h1>
<span class="Bold">TENORETIC®</span><br><span class="Bold">(atenolol and chlorthalidone) Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_8bde3872-6069-4cbd-8d11-5e16188ef980"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">TENORETIC® (atenolol and chlorthalidone) is for the treatment of  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  It combines the antihypertensive activity of two agents:  a beta<span class="Sub">1</span>-selective (cardioselective) hydrophilic blocking agent (atenolol, TENORMIN<span class="Sup">®</span>) and a monosulfonamyl diuretic (chlorthalidone).  Atenolol is Benzeneacetamide, 4-[2'-hydroxy-3'-[(1-methylethyl) amino] propoxy]-.</p>
<div class="Figure">
<a name="id346"></a><img alt="chemical one" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ebcca1e-ca16-4483-429a-aec5dcacd1dc&amp;name=fe61473a-7ca4-44d7-9de1-1e83d820581a-01.jpg">
</div>
<p>Atenolol (free base) is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/mL at 37° C.  It is freely soluble in 1N HCl (300 mg/mL at 25°C) and less soluble in chloroform (3 mg/mL at 25°C). </p>
<p>Chlorthalidone is 2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl) benzene sulfonamide:</p>
<div class="Figure">
<a name="id349"></a><img alt="chemical two" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ebcca1e-ca16-4483-429a-aec5dcacd1dc&amp;name=fe61473a-7ca4-44d7-9de1-1e83d820581a-02.jpg">
</div>
<p>Chlorthalidone has a water solubility of 12 mg/100 mL at 20°C.      </p>
<p>Each TENORETIC 100 Tablet contains:</p>
<p>Atenolol (TENORMIN®).......................................100 mg</p>
<p>Chlorthalidone........................................................  25 mg</p>
<p>Each TENORETIC 50 Tablet contains:</p>
<p>Atenolol (TENORMIN®).........................................50 mg</p>
<p>Chlorthalidone..........................................................25 mg</p>
<p>Inactive ingredients:  magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_5ec6a0c4-8634-455d-ad29-84630be7b935"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9ad2743c-ebdd-415e-be7a-fd2a4dda0453"></a><a name="section-2.1"></a><p></p>
<h2>Tenoretic</h2>
<p class="First">Atenolol and chlorthalidone have been used singly and concomitantly for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  The antihypertensive effects of these agents are additive, and studies have shown that there is no interference with bioavailability when these agents are given together in the single combination tablet.  Therefore, this combination provides a convenient formulation for the concomitant administration of these two entities.  In patients with more severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, TENORETIC may be administered with other antihypertensives such as vasodilators.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d0b27211-638b-4eef-b5c6-8c3e33669f2a"></a><a name="section-2.2"></a><p></p>
<h2>Atenolol</h2>
<p class="First">Atenolol is a beta<span class="Sub">1</span>-selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities.  This preferential effect is not absolute, however, and at higher doses, atenolol inhibits beta<span class="Sub">2</span>-adrenoreceptors, chiefly located in the bronchial and vascular musculature.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_b0c1c7fb-f175-4d28-91bb-d5f56e57c17b"></a><a name="section-3"></a><p></p>
<h1>PHARMACODYNAMICS</h1>
<p class="First">In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: (1) reduction in resting and exercise heart rates and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and (4) reduction in reflex orthostatic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. </p>
<p>A significant beta-blocking effect of atenolol, as measured by reduction of exercise <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, is apparent within one hour following oral administration of a single dose. This effect is maximal at about 2 to 4 hours and persists for at least 24 hours. The effect at 24 hours is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. However, as has been shown for all beta blocking agents, the antihypertensive effect does not appear to be related to plasma level. </p>
<p>In normal subjects, the beta<span class="Sub">1</span>-selectivity of atenolol has been shown by its reduced ability to reverse the beta<span class="Sub">2</span>-mediated vasodilating effect of isoproterenol as compared to equivalent beta-blocking doses of propranolol. In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo controlled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV<span class="Sub">1</span> than nonselective beta blockers, such as propranolol and unlike those agents did not inhibit bronchodilation in response to isoproterenol. </p>
<p>Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus cycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta blockade does not further depress myocardial contractility. Several studies have demonstrated a moderate (approximately 10%) increase in <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> at rest and exercise. </p>
<p>In controlled clinical trials, atenolol given as a single daily dose, was an effective antihypertensive agent providing 24-hour reduction of blood pressure. Atenolol has been studied in combination with thiazide-type diuretics and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine and prazosin, the combination resulting in a larger <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> than with the single agents. The dose range of atenolol is narrow, and increasing the dose beyond 100 mg once daily is not associated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. Several mechanisms have been proposed and include: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, (2) a central effect leading to reduced sympathetic outflow to the periphery and (3) suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy of atenolol with prolonged use.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_f33263c8-3a09-4625-8b5b-f2721a3f03b0"></a><a name="section-4"></a><p></p>
<h1>PHARMACOKINETICS AND METABOLISM</h1>
<p class="First">In man, absorption of an oral dose is rapid and consistent but incomplete. Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces. Peak blood levels are reached between 2 and 4 hours after ingestion. Unlike propranolol or metoprolol, but like nadolol, hydrophilic atenolol undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion. Atenolol also differs from propranolol in that only a small amount (6 - 16%) is bound to proteins in the plasma. This kinetic profile results in relatively consistent plasma drug levels with about a fourfold interpatient variation. There is no information as to the pharmacokinetic effect of atenolol on chlorthalidone. </p>
<p>The elimination half-life of atenolol is approximately 6 to 7 hours and there is no alteration of the kinetic profile of the drug by chronic administration. Following doses of 50 mg or 100 mg, both beta-blocking and antihypertensive effects persist for at least 24 hours. When renal function is impaired, elimination of atenolol is closely related to the glomerular filtration rate; but significant accumulation does not occur until the creatinine clearance <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 35 mL/min/1.73m<span class="Sup">2</span> (see prescribing information for atenolol [TENORMIN®]). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08fbd3a4-406e-4d04-8ad3-8dee8f04fcfd"></a><a name="section-4.1"></a><p></p>
<h2>Atenolol Geriatric Pharmacology</h2>
<p class="First">In general, elderly patients present higher atenolol plasma levels with total clearance values about 50% lower than younger subjects. The half-life is markedly longer in the elderly compared to younger subjects. The reduction of atenolol clearance follows the general trend that the elimination of renally excreted drugs is decreased with increasing age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dd390aaf-1627-4327-84e0-721177435c75"></a><a name="section-4.2"></a><p></p>
<h2>Chlorthalidone</h2>
<p class="First">Chlorthalidone is a monosulfonamyl diuretic which differs chemically from thiazide diuretics in that a double ring system is incorporated in its structure. It is an oral diuretic with prolonged action and low toxicity. The <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> of the drug occurs within 2 hours of an oral dose. It produces <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> with greatly increased excretion of sodium and chloride. At maximal therapeutic dosage, chlorthalidone is approximately equal in its <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effect</span> to comparable maximal therapeutic doses of benzothiadiazine diuretics. The site of action appears to be the cortical diluting segment of the ascending limb of Henle's loop of the nephron.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="powellk11152631422656"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE SECTION</h1>
<p class="First">TENORETIC is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. </p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). </p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly. </p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. </p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy. </p>
<p>This fixed dose combination drug is not indicated for initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="powellk11152631374687"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">TENORETIC is contraindicated in patients with:  <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> greater than first degree; <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <a href="#powellk11152631021046">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this product or to sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="powellk11152631021046"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c81b7c9d-5107-47fe-9fa6-8b09e9545df4"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation is necessary in supporting circulatory function in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and beta blockade carries the potential hazard of further depressing  myocardial contractility and precipitating more severe failure.</p>
<p>IN PATIENTS WITHOUT A HISTORY OF <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">CARDIAC FAILURE</span>, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.  At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients should be treated appropriately according to currently recommended guidelines, and the response observed closely.  If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues despite adequate treatment, TENORETIC should be withdrawn. (See <a href="#powellk11152631069406">DOSAGE AND ADMINISTRATION</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ff2e70ea-8fa9-4d36-9e70-ae47c1a0ceb7"></a><a name="section-7.2"></a><p></p>
<h2>Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></h2>
<p class="First">Since atenolol is excreted via the kidneys, TENORETIC should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>.  Since cumulative effects may develop in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, if progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, TENORETIC should be discontinued.   </p>
<p>In patients with impaired hepatic function or progressive liver disease, minor alterations in fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.  TENORETIC should be used with caution in these patients.     </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c7867cf4-7934-4291-a5b2-6bedd9260858"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span></h2>
<p class="First">Following abrupt cessation of therapy with certain beta-blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, exacerbations of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported.  Therefore, such patients should be cautioned against interruption of therapy without the physician's advice. Even in the absence of overt <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, when discontinuation of TENORETIC is planned, the patient should be carefully observed and should be advised to limit physical activity to a minimum.  TENORETIC should be reinstated if withdrawal symptoms occur. Because <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> is common and may be unrecognized, it may be prudent not to discontinue TENORETIC therapy abruptly even in patients treated only for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ff60e41e-a6bb-47e4-b961-3ceff2da4dbd"></a><a name="section-7.4"></a><p></p>
<h2>Concomitant Use of Calcium Channel Blockers</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem.  Patients with pre-existing conduction abnormalities or <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> are particularly susceptible.  (See <span class="Bold"><a href="#ID_5db409e4-dad4-4701-b126-da37a7e08f4a">PRECAUTIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5e40232c-1615-48bb-8188-f126aa5578d8"></a><a name="section-7.5"></a><p></p>
<h2>Bronchospastic Diseases</h2>
<p class="First"><span class="Bold">PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS.  Because of its relative beta<span class="Sub">1</span>-selectivity, however, TENORETIC may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment.  Since beta<span class="Sub">1</span>-selectivity is not absolute, the lowest possible dose of TENORETIC should be used and a beta<span class="Sub">2</span>-stimulating agent (bronchodilator) should be made available.  If dosage must be increased, dividing the dose should be considered in order to achieve lower peak blood levels.   </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_57e4f313-ef7b-45e7-821a-13400cd9a83b"></a><a name="section-7.6"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6648b917-9e8f-495c-9374-03adedd263eb"></a><a name="section-7.7"></a><p></p>
<h2>Metabolic and Endocrine Effects</h2>
<p class="First">TENORETIC may be used with caution in diabetic patients. Beta blockers may mask <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> occurring with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, but other manifestations such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> may not be significantly affected.  At recommended doses atenolol does not potentiate insulin-induced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and, unlike nonselective beta blockers, does not delay recovery of blood glucose to normal levels.     </p>
<p>Insulin requirements in diabetic patients may be increased, decreased or unchanged; <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during chlorthalidone administration. </p>
<p>Beta-adrenergic blockade may mask certain clinical signs (eg, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.  Abrupt withdrawal of beta blockade might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>; therefore, patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> from whom TENORETIC therapy is to be withdrawn should be monitored closely.     </p>
<p>Because calcium excretion is decreased by thiazides, TENORETIC should be discontinued before carrying out tests for parathyroid function.  Pathologic changes in the parathyroid glands, with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, have been observed in a few patients on prolonged thiazide therapy; however, the common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> such as renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> have not been seen.     </p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur, or acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47a0bb2f-ea25-49ba-a661-0ab22322a8d1"></a><a name="section-7.8"></a><p></p>
<h2>Untreated <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span></h2>
<p class="First">TENORETIC should not be given to patients with untreated <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="powellk11152631251031"></a><a name="section-8"></a><p></p>
<h1>PREGNANCY AND FETAL INJURY</h1>
<p class="First">Atenolol can cause fetal harm when administered to a pregnant woman. Atenolol crosses the placental barrier and appears in cord blood.  Administration of atenolol, starting in the second trimester of pregnancy, has been associated with the birth of infants that are <span class="product-label-link" type="condition" conceptid="72726" conceptname="Light-for-dates with signs of fetal malnutrition">small for gestational age</span>.  No studies have been performed on the use of atenolol in the first trimester and the possibility of fetal injury cannot be excluded.   If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Neonates born to mothers who are receiving atenolol at parturition or breast-feeding may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Caution should be exercised when TENORETIC is administered during pregnancy or to a woman who is breast-feeding. (See <a href="#ID_b55dfe99-178b-412b-a840-86ac82a310ad">PRECAUTIONS, Nursing Mothers</a>.)</p>
<p>TENORETIC was studied for teratogenic potential in the rat and rabbit.  Doses of atenolol/chlorthalidone of 8/2, 80/20, and 240/60 mg/kg/day were administered orally to pregnant rats with no evidence of embryofetotoxicity observed.  Two studies were conducted in rabbits.  In the first study, pregnant rabbits were dosed with 8/2, 80/20, and 160/40 mg/kg/day of atenolol/chlorthalidone.  No teratogenic effects were noted, but embryonic resorptions were observed at all dose levels (ranging from approximately 5 times to 100 times the maximum recommended human dose<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a>).  In the second rabbit study, doses of atenolol/chlorthalidone were 4/1, 8/2, and 20/5 mg/kg/day.  No teratogenic or embryotoxic effects were demonstrated.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd> Based on the maximum dose of 100 mg/day in a 50 kg patient.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_530842d3-56d9-4360-91bc-fc89ae52009c"></a><a name="section-8.1"></a><p></p>
<h2>Atenolol</h2>
<p class="First">Atenolol has been shown to produce a dose-related increase in embryo/fetal resorptions in rats at doses equal to or greater than 50 mg/kg/day or 25 or more times the maximum recommended human antihypertensive dose<a href="#_Ref327868941%20%5Cf%20%5Ch">1</a>.  Although similar effects were not seen in rabbits, the compound was not evaluated in rabbits at doses above 25 mg/kg/day or 12.5 times the maximum recommended human antihypertensive dose<a href="#_Ref327868941%20%5Cf%20%5Ch">1</a>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c375a621-19f0-4bfd-b046-dc9108dbaaae"></a><a name="section-8.2"></a><p></p>
<h2>Chlorthalidone</h2>
<p class="First">Thiazides cross the placental barrier and appear in cord blood.  The use of chlorthalidone and related drugs in pregnant women requires that the anticipated benefits of the drug be weighed against possible hazards to the fetus.  These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and possibly other adverse reactions which have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_5db409e4-dad4-4701-b126-da37a7e08f4a"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_99012a5e-30d9-46e3-92d9-10b840cf83c9"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">TENORETIC may aggravate peripheral arterial circulatory disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8299173b-8059-466e-a51b-7c1f08a2bb65"></a><a name="section-9.2"></a><p></p>
<h2>Electrolyte and Fluid Balance Status</h2>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>Patients should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>; i.e., <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> include dryness of the mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Measurement of potassium levels is appropriate especially in elderly patients, those receiving digitalis preparations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients whose dietary intake of potassium is abnormally low, or those suffering from gastrointestinal complaints. </p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, or during concomitant use of corticosteroids or ACTH. </p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (eg, increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>). <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may be avoided or treated by use of potassium supplements or foods with a high potassium content.</p>
<p>Any chloride deficit during thiazide therapy is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than administration of salt except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_f2c9f23f-a860-4642-a7e0-9bfec3b4723e"></a><a name="section-9.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">TENORETIC may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with TENORETIC plus a catecholamine depletor (eg, reserpine) should be closely observed for evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. </p>
<p>Calcium channel blockers may also have an additive effect when given with TENORETIC. (See <a href="#powellk11152631021046">WARNINGS</a>.)</p>
<p>Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> when administered with beta blockers. </p>
<p>Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers.</p>
<p>Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrine. Thiazides may increase the responsiveness to tubocurarine.</p>
<p>Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.</p>
<p>Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Read prescribing information for lithium preparations before use of such preparations with TENORETIC.</p>
<p>Beta blockers may exacerbate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.</p>
<p>While taking beta blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_86878271-8a3c-493e-8e39-779be11cbe52"></a><a name="section-9.4"></a><p></p>
<h2>Other Precautions </h2>
<p class="First">In patients receiving thiazides, sensitivity reactions may occur with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The possible exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported. The antihypertensive effects of thiazides may be enhanced in the postsympathectomy patient.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_850a69b2-ace5-4478-a779-b40b60665e46"></a><a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Two long-term (maximum dosing duration of 18 or 24 months) rat studies and one long-term (maximum dosing duration of 18 months) mouse study, each employing dose levels as high as 300 mg/kg/day or 150 times the maximum recommended human antihypertensive dose<span class="Sup">1</span>, did not indicate a carcinogenic potential of atenolol. A third (24 month) rat study, employing doses of 500 and 1,500 mg/kg/day (250 and 750 times the maximum recommended human antihypertensive dose<span class="Sup">1</span>) resulted in increased incidences of benign adrenal medullary tumors in males and females, mammary fibroadenomas in females, and anterior <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> and thyroid parafollicular cell carcinomas in males. No evidence of a mutagenic potential of atenolol was uncovered in the dominant lethal test (mouse), <span class="Italics">in vivo</span> cytogenetics test (Chinese hamster) or Ames test (S typhimurium). </p>
<p>Fertility of male or female rats (evaluated at dose levels as high as 200 mg/kg/day or 100 times the maximum recommended human dose<span class="Sup">1</span>) was unaffected by atenolol administration. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_082ca8be-3ad3-4952-896f-a3ff5c82c6d8"></a><a name="section-9.6"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First">Six month oral administration studies were conducted in rats and dogs using TENORETIC doses up to 12.5 mg/kg/day (atenolol/chlorthalidone 10/2.5 mg/kg/day -- approximately five times the maximum recommended human antihypertensive dose<span class="Sup">1</span>). There were no functional or morphological abnormalities resulting from dosing either compound alone or together other than minor changes in heart rate, blood pressure and urine chemistry which were attributed to the known pharmacologic properties of atenolol and/or chlorthalidone.</p>
<p>Chronic studies of atenolol performed in animals have revealed the occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels (starting at 15 mg/kg/day or 7.5 times the maximum recommended human antihypertensive dose<a href="#_Ref327868941%20%5Ch">1</a>) and increased incidence of atrial degeneration of hearts of male rats at 300 but not 150 mg atenolol/kg/day (150 and 75 times the maximum recommended human antihypertensive dose,<a href="#_Ref327868941%20%5Ch">1</a> respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_37c9d3c2-7a0d-4ee3-b6b1-fbe1365826df"></a><a name="section-9.7"></a><p></p>
<h2>Use in Pregnancy</h2>
<p class="First">Pregnancy Category D: See <a href="#powellk11152631251031">WARNINGS - Pregnancy and Fetal Injury</a></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_b55dfe99-178b-412b-a840-86ac82a310ad"></a><a name="section-9.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Atenolol is excreted in human breast milk at a ratio of 1.5 to 6.8 when compared to the concentration in plasma. Caution should be exercised when atenolol is administered to a nursing woman. Clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> has been reported in breast-fed infants. Premature infants, or infants with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, may be more likely to develop adverse effects.</p>
<p>Neonates born to mothers who are receiving atenolol at parturition or breast-feeding may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Caution should be exercised when TENORETIC is administered during pregnancy or to a woman who is breast-feeding. (See <a href="#powellk11152631251031">WARNINGS, Pregnancy and Fetal Injury</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_16021223-ba97-4ef3-a1b0-b7b00af96b4d"></a><a name="section-10"></a><p></p>
<h1>PEDIATRIC USE</h1>
<p class="First">Safety and effectiveness in pediatric patients  have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_f92fc76f-d1f2-4c18-8d4e-a8504fff0abd"></a><a name="section-11"></a><p></p>
<h1>GERIATRIC USE</h1>
<p class="First">Clinical studies of TENORETIC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_c1974c75-8571-4dbd-9320-8137eecb763a"></a><a name="section-12"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">TENORETIC is usually well tolerated in properly selected patients.  Most adverse effects have been mild and transient.  The adverse effects observed for TENORETIC are essentially the same as those seen with the individual components. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9ba094c0-630f-4ae8-9036-d63b3e46f7e0"></a><a name="section-12.1"></a><p></p>
<h2>Atenolol</h2>
<p class="First">The frequency estimates in the following table were derived from controlled studies in which adverse reactions were either volunteered by the patient (US studies) or elicited, eg, by checklist (foreign studies).  The reported frequency of elicited adverse effects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered.  Where frequency of adverse effects for atenolol and placebo is similar, causal relationship to atenolol is uncertain.</p>
<table>
<col width="36%">
<col width="10%">
<col width="10%">
<col width="12%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="2">
<p class="First">Volunteered</p>
<p><span class="Underline">(US Studies)</span></p>
</td>
<td align="center" colspan="2">
<p class="First">Total − Volunteered</p>
<p>and Elicited</p>
<p><span class="Underline">(Foreign + US Studies)</span></p>
</td>
</tr>
<tr>
<td></td>
<td>
<p class="First">Atenolol</p>
<p>(n=164)</p>
<p>%</p>
</td>
<td align="center">
<p class="First">Placebo</p>
<p>(n=206)</p>
<p>%</p>
</td>
<td>
<p class="First">Atenolol</p>
<p>(n=399)</p>
<p>%</p>
</td>
<td>
<p class="First">Placebo</p>
<p>(n=407)</p>
<p>%</p>
</td>
</tr>
<tr>
<td><p class="First">CARDIOVASCULAR</p></td>
<td colspan="4"></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Cold Extremities</span></p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">0.5</p></td>
<td align="center"><p class="First">12</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural Hypotension</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Leg Pain</span></p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">0.5</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td>
<p class="First">CENTRAL NERVOUS SYSTEM/</p>
<p>NEUROMUSCULAR</p>
</td>
<td colspan="4"></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">13</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">0.5</p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">0.2</p></td>
</tr>
<tr>
<td><p class="First">  Light-headedness</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0.7</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0.5</p></td>
<td align="center"><p class="First">26</p></td>
<td align="center"><p class="First">13</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0.7</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">0.5</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">0.5</p></td>
<td align="center"><p class="First">12</p></td>
<td align="center"><p class="First">9</p></td>
</tr>
<tr>
<td><p class="First">  Dreaming</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">GASTROINTESTINAL</p></td>
<td colspan="4"></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First">RESPIRATORY (see <a href="#powellk11152631021046">WARNINGS</a>)</p></td>
<td colspan="4"></td>
</tr>
<tr>
<td><p class="First">  Wheeziness</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">0</p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr class="Last">
<td><p class="First">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center"><p class="First">0.6</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
</tbody>
</table>
<p>During postmarketing experience, the following have been reported in temporal relationship to the use of the drug:  elevated liver enzymes and/or bilirubin, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, Peyronie's disease, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> which may be associated with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>, psychoses, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, reversible <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>, <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.  TENORETIC, like other beta blockers, has been associated with the development of antinuclear antibodies (ANA), <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">lupus syndrome</span>, and Raynaud’s phenomenon.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_339018c3-fb0e-407c-b7c1-1e8418fe9b54"></a><a name="section-12.2"></a><p></p>
<h2>Chlorthalidone</h2>
<p class="First">Cardiovascular:  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>; Gastrointestinal:  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; CNS:  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>; Hematologic:  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:  <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>) (<span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), Lyell's syndrome (<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>); Miscellaneous:  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.  Clinical trials of TENORETIC conducted in the United States (89 patients treated with TENORETIC) revealed no new or unexpected adverse effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7030293f-9c11-40fa-9bea-714e6302011a"></a><a name="section-12.3"></a><p></p>
<h2>POTENTIAL ADVERSE EFFECTS</h2>
<p class="First">In addition, a variety of adverse effects not observed in clinical trials with atenolol but reported with other beta-adrenergic blocking agents should be considered potential adverse effects of atenolol.  Nervous System:  Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, decreased performance on neuropsychometrics; Cardiovascular: Intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (see <a href="#powellk11152631374687">CONTRAINDICATIONS</a>); Gastrointestinal: Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; Hematologic:  <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; Allergic:  Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6b7b8be9-34b3-4859-8161-217823589d80"></a><a name="section-12.3.1"></a><p></p>
<h3>Miscellaneous</h3>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> and/or <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span> associated with the use of beta-adrenergic blocking drugs.  The reported incidence is small, and, in most cases, the symptoms have cleared when treatment was withdrawn.  Discontinuance of the drug should be considered if any such reaction is not otherwise explicable.  Patients should be closely monitored following cessation of therapy.  (See <a href="#powellk11152631069406">DOSAGE AND ADMINISTRATION</a>.)</p>
<p>The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta blocker practolol has not been reported with atenolol (TENORMIN).  Furthermore, a number of patients who had previously demonstrated established practolol reactions were transferred to atenolol (TENORMIN) therapy with subsequent resolution or quiescence of the reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3bf17e91-3636-47c6-a057-f026487ea4a7"></a><a name="section-12.3.2"></a><p></p>
<h3>Clinical Laboratory Test Findings</h3>
<p class="First">Clinically important changes in standard laboratory parameters were rarely associated with the administration of TENORETIC.  The changes in laboratory parameters were not progressive and usually were not associated with clinical manifestations.  The most common changes were increases in uric acid and decreases in serum potassium.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="powellk11152631143296"></a><a name="section-13"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No specific information is available with regard to overdosage and TENORETIC in humans.  Treatment should be symptomatic and supportive and directed to the removal of any unabsorbed drug by induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, or administration of activated charcoal.  Atenolol can be removed from the general circulation by hemodialysis.  Further consideration should be given to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> by established procedures. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47619281-23ad-42e7-a50a-d8259dcff65a"></a><a name="section-13.1"></a><p></p>
<h2>Atenolol</h2>
<p class="First">Overdosage with atenolol has been reported with patients surviving acute doses as high as 5 g.   One <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was reported in a man who may have taken as much as 10 g acutely.  </p>
<p>The predominant symptoms reported following atenolol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, disorder of respiratory drive, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, sinus pause, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.  Additionally, common effects associated with overdosage of any beta-adrenergic blocking agent are <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and/or <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.  Other treatment modalities should be employed at the physician's discretion and may include: </p>
<p><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">BRADYCARDIA</span>:  Atropine 1-2 mg intravenously.  If there is no response to vagal blockade, give isoproterenol cautiously.  In refractory cases, a transvenous cardiac pacemaker may be indicated.  Glucagon in a 10 mg intravenous bolus has been reported to be useful.  If required, this may be repeated or followed by an intravenous infusion of glucagon 1-10 mg/h depending on response.</p>
<p><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">HEART BLOCK</span> (SECOND OR THIRD DEGREE):  Isoproterenol or transvenous pacemaker.</p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span>:  Digitalize the patient and administer a diuretic. Glucagon has been reported to be useful.</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">HYPOTENSION</span>:  Vasopressors such as dopamine or norepinephrine (levarterenol). Monitor blood pressure continuously.</p>
<p><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">BRONCHOSPASM</span>:  A beta<span class="Sub">2</span>-stimulant such as isoproterenol or terbutaline and/or aminophylline.</p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">HYPOGLYCEMIA</span>:  Intravenous glucose.</p>
<p><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">ELECTROLYTE DISTURBANCE</span>:  Monitor electrolyte levels and renal function.  Institute measures to maintain hydration and electrolytes.</p>
<p>Based on the severity of symptoms, management may require intensive support care and facilities for applying cardiac and respiratory support.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a4b5567c-cb37-4b9d-aa1c-abb432b6e5b4"></a><a name="section-13.2"></a><p></p>
<h2>Chlorthalidone</h2>
<p class="First">Symptoms of chlorthalidone <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and disturbances of electrolyte balance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="powellk11152631069406"></a><a name="section-14"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">DOSAGE MUST BE INDIVIDUALIZED. (See <a href="#powellk11152631422656">INDICATIONS AND USAGE</a>.) </p>
<p>Chlorthalidone is usually given at a dose of 25 mg daily; the usual initial dose of atenolol is 50 mg daily.  Therefore, the initial dose should be one TENORETIC 50 tablet given once a day.  If an optimal response is not achieved, the dosage should be increased to one TENORETIC 100 tablet given once a day. </p>
<p>When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>. </p>
<p>Since atenolol is excreted via the kidneys, dosage should be adjusted in cases of severe impairment of renal function.  No significant accumulation of atenolol occurs until creatinine clearance <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 35 mL/min/1.73m<span class="Sup">2</span> (normal range is 100-150 mL/min/1.73m<span class="Sup">2</span>); therefore, the following maximum dosages are recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<table>
<col width="22%">
<col width="22%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td align="center">
<p class="First">Creatinine Clearance</p>
<p>(mL/min/1.73m<span class="Sup">2</span>)</p>
</td>
<td align="center">
<p class="First">Atenolol</p>
<p>Elimination Half-Life</p>
<p>(hrs)</p>
</td>
<td align="center"><p class="First">Maximum Dosage</p></td>
</tr>
<tr>
<td align="center"><p class="First">15-35</p></td>
<td align="center"><p class="First">16-27</p></td>
<td align="center"><p class="First">50 mg daily</p></td>
</tr>
<tr class="Last">
<td align="center"><p class="First">&lt;15</p></td>
<td align="center"><p class="First">&gt;27</p></td>
<td align="center"><p class="First">50 mg every other day </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_c00c6b11-b604-4bd1-bfa0-e53a011331f3"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">TENORETIC 50 Tablets (atenolol 50 mg and chlorthalidone 25 mg), NDC 0310-0115, (white, round, biconvex, uncoated tablets with TENORETIC on one side and 115 on the other side, bisected) are supplied in bottles of 100 tablets. </p>
<p>TENORETIC 100 Tablets (atenolol 100 mg and chlorthalidone 25 mg), NDC 0310-0117, (white, round, biconvex, uncoated tablets with TENORETIC on one side and 117 on the other side) are supplied in bottles of 100 tablets.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_68df9aac-60dd-4d07-838a-d584ba8e227b"></a><a name="section-15.1"></a><p></p>
<h2>Storage:</h2>
<p class="First">Store at controlled room temperature, 20-25°C (68-77°F) [see USP].  Dispense in well-closed, light-resistant containers.</p>
<p>TENORETIC is a trademark of the AstraZeneca group of companies.</p>
<p>©AstraZeneca 2012</p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>Rev. 10/2012</p>
<p><span class="Bold">AstraZeneca</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_c760cc9a-eacc-4e0c-9eea-aa0b7916e1bf"></a><a name="section-16"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 50 mg</h1>
<p class="First">NDC 0310-0115-10</p>
<p>100 tablets</p>
<p>Tenoretic® 50</p>
<p>Each tablet contains:</p>
<p>50 mg atenolol and</p>
<p>25 mg chlorthalidone</p>
<p>Rx only</p>
<p>Manufactured for:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>By:  IPR Pharmaceuticals, Inc.</p>
<p>Canóvanas, PR 00729</p>
<p>AstraZeneca</p>
<div class="Figure">
<a name="id365067749"></a><img alt="TENORETIC 50 Bottle Label 100 tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ebcca1e-ca16-4483-429a-aec5dcacd1dc&amp;name=fe61473a-7ca4-44d7-9de1-1e83d820581a-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_0aacebd8-8e61-42be-8178-27a93219a483"></a><a name="section-17"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 100 mg</h1>
<p class="First">NDC 0310-0117-10</p>
<p>100 tablets</p>
<p>Tenoretic® 100</p>
<p>Each tablet contains:</p>
<p>100 mg atenolol and</p>
<p>25 mg chlorthalidone</p>
<p>Rx only</p>
<p>Manufactured for:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>By:  IPR Pharmaceuticals, Inc.</p>
<p>Canóvanas, PR 00729</p>
<p>AstraZeneca</p>
<div class="Figure">
<a name="id365067754"></a><img alt="Tenoretic 100 Bottle Label 100 tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ebcca1e-ca16-4483-429a-aec5dcacd1dc&amp;name=fe61473a-7ca4-44d7-9de1-1e83d820581a-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TENORETIC 		
					</strong><br><span class="contentTableReg">atenolol and chlorthalidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0117</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATENOLOL</strong> (ATENOLOL) </td>
<td class="formItem">ATENOLOL</td>
<td class="formItem">100 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CHLORTHALIDONE</strong> (CHLORTHALIDONE) </td>
<td class="formItem">CHLORTHALIDONE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TENORETIC;117</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0117-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018760</td>
<td class="formItem">09/01/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TENORETIC 		
					</strong><br><span class="contentTableReg">atenolol and chlorthalidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATENOLOL</strong> (ATENOLOL) </td>
<td class="formItem">ATENOLOL</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CHLORTHALIDONE</strong> (CHLORTHALIDONE) </td>
<td class="formItem">CHLORTHALIDONE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TENORETIC;115</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0310-0115-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018760</td>
<td class="formItem">09/01/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>AstraZeneca Pharmaceuticals LP
							(054743190)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>AstraZeneca PLC (230790719)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">IPR Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">156931248</td>
<td class="formItem">MANUFACTURE(0310-0117, 0310-0115)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fe61473a-7ca4-44d7-9de1-1e83d820581a</div>
<div>Set id: 0ebcca1e-ca16-4483-429a-aec5dcacd1dc</div>
<div>Version: 8</div>
<div>Effective Time: 20121031</div>
</div>
</div> <div class="DistributorName">AstraZeneca Pharmaceuticals LP</div></p>
</body></html>
